glp-1 and metabolism receptor agonists next-generation metabolic hormone therapies in chronic kidney disease GLP-1 and Microbiome Repair for
Description
Patients treated with Hepzato saw a 73.6% disease control rate
All authors discussed the results and contributed to writing and editing the final manuscript
The medication can: Decrease appetite : By signaling the brain to feel full, which helps lower calorie intake
we master metabolic health
10.1016/j.joca.2021.05.007 27 LepetsosP.PapavassiliouK
